GLOBAL-SWITCH
Global Switch, a leading owner, operator and developer of large scale network dense, carrier and cloud neutral multi-tenanted data centres in Europe and Asia-Pacific has announced that in response to growing demand construction has started on the first stage of a new data centre in Amsterdam.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200624005069/en/
The 32,000 sq m data centre, Global Switch Amsterdam East, will be built immediately adjacent to the existing Amsterdam West facility located in the Slotervaart/Overtoomseveld district, close to the main Dutch cable infrastructure, the financial district and city centre. Global Switch Amsterdam is the only multi-tenant provider in the city with a dedicated mains supply, and once all stages of the new data centre are complete, the utility power supply capacity will increase by 40MVA, bringing the campus total to 72MVA supplied at 50kV.
In contrast to the recent moratorium on granting new data centre planning consents, importantly Global Switch Amsterdam East is a known project with Gemeente Amsterdam (City of Amsterdam) and is not impacted either by the widely announced ‘building stop’ or affected by power availability across the Metropolitan Region of Amsterdam.
Similar to other Global Switch developments, energy efficiency is at the core of the design. Amsterdam East will incorporate the latest technologies such a flooded room cooling design with hot aisle containment allowing flexible IT rack load deployment. The cooling will be generated using a free-cooling water-based cooling system and will allow the heat to be exported to the local community. The data centre will be targeting an annualised design Power Usage Effectiveness (PUE) of less than 1.2 and a BREEAM "Very Good" certification. In addition, as part of Global Switch’s comprehensive Energy Management Programme, customers will be offered 100% green energy.
John Corcoran, CEO Global Switch , said, “We are continuing to see demand for high quality, resilient and energy efficient data centres providing multiple connectivity options particularly from global hyperscale cloud providers looking for highly experienced data centre operators, such as Global Switch, as well as demand from European, US and Asian customers. We are therefore delighted to have now started construction of Global Switch Amsterdam East which will be our fourteenth data centre.”
Jasper Lankhorst, Managing Director Global Switch Amsterdam , said, “It is very exciting to be announcing this substantial addition of world class technical data centre capacity to our Amsterdam campus, particularly at a time when there is a permit stop for new data centre developments in the city and a shortage in power availability in some places of the Amsterdam Metro Area. With the acceleration of the digital economy, Global Switch Amsterdam East will provide an Open Compute Platform ready environment enabling customers to deploy at scale both with speed and cost effectively. As with all our data centres, customers will also benefit from bespoke data centre solutions, as well as a highly resilient and secure space for housing mission critical IT equipment.”
Global Switch Amsterdam West is a core node not just for the Netherlands, but also for Europe and beyond. It is one of the most connected hubs in the country and currently hosts a multitude of global and national telecommunications and cloud providers, AMS-IX and NL-IX as well as a wide range of internet services providers. With direct fibre connections between the two data centres, customers of Amsterdam East will be able to access this connectivity rich environment and will benefit from a wide choice of cloud and network providers as well as direct access to the global IP backbone. The two data centres will provide a total of four diverse entry points and four interconnected Meet Me Rooms ensuring highly resilient connections.
Peter van Burgel, CEO, AMS-IX , said, “We welcome this news by our long-term partner Global Switch. This announcement underlines the importance of the Amsterdam region as one of the largest connectivity hubs in the world and as a desirable climate for digital businesses. It also shows that the digitalisation continues to be a strong, sustainable driver for growth, even in a time when building options are challenging and the economic outlook is uncertain.”
Stijn Grove, Managing Director Dutch Data Center Association (DDA) , said, “The impact of digitalisation on our economy and society is immense. The recent events have only made people more aware that digitalisation is the sustainable way forward to grow our economy. A sound digital foundation is of crucial importance to achieve this. The Metro Region Amsterdam (MRA) is one of the key data hubs in the world and known as the Digital Gateway to Europe. Global Switch’ expansion in the MRA region will strengthen this international position as key data hub even further, and the Dutch and international economy as a whole. We are proud to have Global Switch as a member of the association and congratulate them with their expansion.”
Technical Snapshot
- Full access to the existing network-dense, low-latency environment with a multitude of carriers and network service providers.
- Access to peering platforms AMS-IX, NL-IX and all major cloud platforms.
- Hyperconnected and ideally located adjacent to the main regional and international fibre routes.
- Built in accordance to the highest operational standards with matching SLA’s.
- Bespoke solutions with scalable space and power.
- Open Compute Platform (OCP) facility compliance.
- Environmentally sustainable targeting a PUE of less than 1.2.
- Certified ISO9001, 14001, 27001, 50001, OHSAS 18001, AMS-IX, PCI-DSS, ISAE 3402 compliant.
About Global Switch
Global Switch is a leading owner, operator and developer of large-scale, carrier and cloud neutral, multi-customer data centres in Europe and Asia-Pacific. Founded in 1998, Global Switch has a proven business model, demonstrable track record and is the highest credit rated data centre company in the world with investment grade credit ratings from Fitch, Moody’s and Standard & Poor’s.
Global Switch is a vital and strategic partner for customers that require secure and resilient data centre services with scalable capacity and a high-level customer service. The Company's focus is on highly resilient, central, low latency, network dense locations in prime city centre locations and internet hubs close to its customers on the edge of financial and business districts. Global Switch’s data centres operate exclusively in the Tier I markets of Europe and Asia-Pacific to Tier III or higher and currently total around 390,000 sq m (4,200,000 sq ft) of floor space and are occupied by a broad range of customers, global and national, large and small including government organisations, financial institutions, enterprises, global systems integrators, telecommunication carriers, cloud and managed service providers and other hosting businesses.
For more information visit: www.globalswitch.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200624005069/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom